Table 6.
The top 10 most highly cited documents in the field of pemphigus treatment.
| Rank | First authors | Title and Publication year | Citations | DOI | Journals |
|---|---|---|---|---|---|
| 1 | Joly, P | First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial (2017) | 154 | 10.1016/S0140-6736(17)30070-3 | Lancet |
| 2 | Kasperkiewicz, M | Pemphigus (2017) | 82 | 10.1038/nrdp.2017.26 | Nature Reviews Disease Primers |
| 3 | Murrell, DF | Diagnosis and management of pemphigus: Recommendations of an international panel of experts (2020) | 66 | 10.1016/j.jaad.2018.02.021 | Journal of the American Academy of Dermatology |
| 4 | Hertl, M | Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) (2015) | 59 | 10.1111/jdv.12772 | Journal of the European Society of Dermatology and Venereology |
| 5 | Murrell, DE | Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus (2008) | 56 | 10.1016/j.jaad.2008.01.012 | Journal of the American Academy of Dermatology |
| 6 | Joly, P | A single cycle of rituximab for the treatment of severe pemphigus (2007) | 54 | 10.1056/NEJMoa067752 | New England Journal of Medicine |
| 7 | Ahmed, AR | Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin (2006) | 53 | 10.1056/NEJMoa062930 | New England Journal of Medicine |
| 8 | Harman, KE | British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017(2017) | 50 | 10.1111/bjd.15930 | British Journal of Dermatology |
| 9 | Schmidt, E | Pemphigus (2019) | 48 | 10.1016/S0140-6736(19)31778-7 | Lancet |
| 10 | Didona, D | Pemphigus: Current and Future Therapeutic Strategies (2019) | 44 | 10.3389/fimmu.2019.01418 | Frontiers in immunology |